|
11 Mar 2020 |
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
|
|
11 Mar 2020 |
ImmunityBio Announces Durable Virus Control of SHIV Without Anti-Retroviral Therapy by Activating NK and Memory T Cells With N-803, an IL-15 Superagonist
|
|
11 Mar 2020 |
NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer
|
|
11 Mar 2020 |
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer
|
|
11 Mar 2020 |
Notice of Capital and Business Alliance between Heartseed and MEDIPAL HOLDINGS
|
|
11 Mar 2020 |
Heartseed and ITOCHU CHEMICAL FRONTIER Sign Capital Alliance Agreement to Explore iPSC and Cardiomyocyte Business Opportunities
|
|
11 Mar 2020 |
Kuur Therapeutics Launches to Develop and Commercialize “Off-the-shelf” CAR-NKT Cell Therapies Targeting Hematological and Solid Tumors
|
|
11 Mar 2020 |
Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial
|
|
10 Mar 2020 |
Athenex Announces FDA Acceptance for Filing of U.S. NDA for Tirbanibulin Ointment in Actinic Keratosis
|
|
10 Mar 2020 |
Myovant Sciences Submits Marketing Authorization Application to the European Medicines Agency for Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
|
|
10 Mar 2020 |
Santen and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration
|
|
10 Mar 2020 |
First Patient Dosed in IPH5201 Phase I Clinical Trial in Advanced Solid Tumors
|
|
10 Mar 2020 |
Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development
|
|
10 Mar 2020 |
Bridge Biotherapeutics Enters AI-based Research Collaboration with Atomwise to Expand Pellino Inhibitor Pipeline
|
|
10 Mar 2020 |
Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease
|
|
10 Mar 2020 |
Mesoblast to evaluate anti-inflammatory cell therapy remestemcel-L for treatment of COVID-19 lung disease
|
|
09 Mar 2020 |
GEMoaB Announces First Patient Apheresed in a Phase IA Study With Lead Product Candidate From Rapidly Switchable Universal CAR-T Platform (UniCAR) in CD123 Positive Relapsed/Refractory Acute Leukemias
|
|
09 Mar 2020 |
ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing
|
|
09 Mar 2020 |
CEL-SCI Initiates Development of Immunotherapy to Treat COVID-19 Coronavirus Infection
|
|
09 Mar 2020 |
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review
|
